Richard William Fairman
CEO & Director
Welcome to this presentation of CVS Group’s interim results for the six-month period to December 2025. I’m Richard Fairman, CEO. And later, you will also hear from Robin Alfonso, our Chief Financial Officer; and Paul Higgs, our Chief Veterinary Officer.
Our purpose at CVS is to give the best possible care to as many animals as possible, and I’m pleased to report on continued progress in the period. We completed our step-up from AIM to the main market on the 29th of January 2026, and we hope this will bring benefits from improved liquidity, access to a more diverse pool of capital, index inclusion for March and an increase in our profile as a company.
We have launched our new consumer-facing U.K. companion animal joint brand under CVS Vets, and you will see this reflected in this presentation. Now this reflects the care, value and service, which we are renowned for as a trusted partner for our clients. Our presence in Australia is growing with three acquisitions completed in the period and a further two practice acquisitions completed so far in the second half of the year. We have continued our disciplined capital investment, improving our facilities, clinical equipment and technology, and we are confident this investment will drive long-term growth in shareholder value.
We welcome the launch by DEFRA of a consultation into the outdated Veterinary Surgeons Act from 1966, and we are engaging with that process and encouraging CVS colleagues to do so. And we look forward to the CMA’s final decision in the coming weeks. We continue to trade in
Read the full article here
